Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ALDX 
Aldeyra The (ALDX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/13/2025: ALDX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $9.67
1 Year Target Price $9.67
| 5 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -27.33% | Avg. Invested days 31 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 11/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 302.02M USD | Price to earnings Ratio - | 1Y Target Price 9.67 |
Price to earnings Ratio - | 1Y Target Price 9.67 | ||
Volume (30-day avg) 7 | Beta 0.83 | 52 Weeks Range 1.14 - 7.20 | Updated Date 11/14/2025 |
52 Weeks Range 1.14 - 7.20 | Updated Date 11/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.73 |
Earnings Date
Report Date 2025-11-05 | When - | Estimate -0.245 | Actual -0.13 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -28.94% | Return on Equity (TTM) -64.31% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 259710734 | Price to Sales(TTM) - |
Enterprise Value 259710734 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.5 | Shares Outstanding 60162773 | Shares Floating 48748692 |
Shares Outstanding 60162773 | Shares Floating 48748692 | ||
Percent Insiders 3.09 | Percent Institutions 57.78 |
Upturn AI SWOT
Aldeyra The
Company Overview
History and Background
Aldeyra Therapeutics, Inc. is a biotechnology company focused on developing and commercializing innovative therapies to improve the lives of patients with immune-mediated diseases. Founded in 2004, Aldeyra initially focused on aldehyde dehydrogenase (ALDH) enzymes. Over time, Aldeyra has expanded its focus to broader immune-mediated diseases.
Core Business Areas
- Ophthalmology: Aldeyra focuses on developing therapies for ocular diseases, including allergic conjunctivitis and dry eye disease.
- Systemic Immune-Mediated Diseases: Aldeyra explores the development of therapies to treat systemic immune-mediated diseases.
Leadership and Structure
The leadership team consists of Dr. Todd C. Brady (CEO), and Richard Edelson (President). The company operates with a functional organizational structure centered around research, clinical development, and commercialization.
Top Products and Market Share
Key Offerings
- Reproxalap: Reproxalap is a small-molecule RASP (reactive aldehyde species) inhibitor in late-stage development for allergic conjunctivitis and dry eye disease. Market share data is not yet available as the product is not yet approved but peak sales expectations are in the hundreds of millions. Competitors for allergic conjunctivitis include Alcon (ALC) and Bausch + Lomb (BLCO). Competitors for dry eye include Novartis (NVS) and AbbVie (ABBV).
- ADX-2191: ADX-2191 is an intravitreal formulation of methotrexate in development for proliferative vitreoretinopathy (PVR). Market data is not available since it is currently in the development pipeline. Competitors for PVR include Alcon and other companies focused on vitreoretinal surgery solutions.
Market Dynamics
Industry Overview
The pharmaceutical industry, particularly the segments focused on ophthalmology and immune-mediated diseases, is characterized by high competition and rigorous regulatory requirements. Companies invest heavily in research and development to bring innovative therapies to market.
Positioning
Aldeyra positions itself as an innovator in the ophthalmology and immune-mediated disease space, with a focus on developing therapies with novel mechanisms of action. Its RASP inhibitor technology gives it a competitive edge. It has a competitive niche in dry eye disease space, but it also faces competition from large companies with already-established drugs for dry eye.
Total Addressable Market (TAM)
The TAM for dry eye disease and allergic conjunctivitis is estimated to be several billion dollars globally. Aldeyra aims to capture a significant share of these markets with Reproxalap. The TAM for PVR is smaller, but ADX-2191 has the potential to address an unmet medical need.
Upturn SWOT Analysis
Strengths
- Novel RASP inhibitor technology
- Late-stage product candidates
- Experienced management team
- Focus on unmet medical needs
Weaknesses
- Reliance on successful clinical trial outcomes
- Dependence on regulatory approvals
- Limited commercial infrastructure
- History of losses
Opportunities
- Potential to expand product pipeline through acquisitions or licensing
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical data for Reproxalap
Threats
- Competition from established pharmaceutical companies
- Unfavorable regulatory decisions
- Clinical trial failures
- Patent challenges
Competitors and Market Share
Key Competitors
- NVS
- ABBV
- ALC
- BLCO
Competitive Landscape
Aldeyra is at a disadvantage currently because of its lack of commercialized products compared to its competitors, although they have a promising novel therapy, and niche areas. In dry eye and allergic conjuctivitis, Novartis, AbbVie, Alcon and Bausch + Lomb are established players with proven products and established brand recognition. However, Aldeyra's RASP inhibitor offers a different mechanism of action that could prove advantageous. The main advantage will be regulatory approval, successful commercialization and revenue.
Growth Trajectory and Initiatives
Historical Growth: Aldeyra's historical growth is measured by advancement of clinical programs and successful fundraising, not by traditional revenue growth.
Future Projections: Future growth is contingent on successful Reproxalap approval and commercialization, and further development of pipeline programs. Analyst estimates for future revenue vary greatly depending on approval timelines.
Recent Initiatives: Recent initiatives include filing of Reproxalap NDA and advancement of ADX-2191 into clinical trials.
Summary
Aldeyra Therapeutics is a clinical-stage company focused on ophthalmology and immune-mediated diseases, with promising novel RASP inhibitor technology. The company needs approval and successful commercialization of Reproxalap. It needs to expand beyond their first FDA approval. Clinical trial outcomes and regulatory decisions are key to the company's success, and its commercial infrastructure will need to be built out or partnered with a larger company. It has a history of losses but good recent revenue.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The data provided is based on publicly available information and may not be complete or accurate. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Aldeyra The
Exchange NASDAQ | Headquaters Lexington, MA, United States | ||
IPO Launch date 2014-05-02 | CEO, President & Director Dr. Todd C. Brady M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 8 | Website https://www.aldeyra.com |
Full time employees 8 | Website https://www.aldeyra.com | ||
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platform, including ADX 248, ADX 743, ADX 631, ADX 246, and other product candidates in development for inflammatory and metabolic diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.